Incyte Corporation (NASDAQ:INCY) insider Paul Trower sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $125.25, for a total transaction of $375,750.00. Following the completion of the transaction, the insider now directly owns 11,853 shares of the company’s stock, valued at approximately $1,484,588.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Paul Trower also recently made the following trade(s):

  • On Wednesday, July 5th, Paul Trower sold 3,000 shares of Incyte Corporation stock. The shares were sold at an average price of $126.18, for a total transaction of $378,540.00.
  • On Monday, June 5th, Paul Trower sold 3,000 shares of Incyte Corporation stock. The shares were sold at an average price of $132.50, for a total transaction of $397,500.00.

Shares of Incyte Corporation (INCY) traded up 2.56% on Monday, hitting $132.00. 1,038,401 shares of the stock traded hands. The stock has a 50-day moving average price of $130.23 and a 200 day moving average price of $129.04. Incyte Corporation has a 12-month low of $75.52 and a 12-month high of $153.15. The stock’s market cap is $27.15 billion.

Incyte Corporation (NASDAQ:INCY) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.01. Incyte Corporation had a negative net margin of 11.77% and a negative return on equity of 21.57%. The company had revenue of $326.40 million for the quarter, compared to analyst estimates of $318.45 million. During the same quarter last year, the business earned $0.18 EPS. The company’s revenue for the quarter was up 32.5% on a year-over-year basis. On average, analysts anticipate that Incyte Corporation will post ($0.77) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Incyte Corporation (NASDAQ:INCY) Insider Sells $375,750.00 in Stock” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/08/07/incyte-corporation-nasdaqincy-insider-sells-375750-00-in-stock.html.

A number of research firms have recently weighed in on INCY. TheStreet raised shares of Incyte Corporation from a “d+” rating to a “c” rating in a research report on Wednesday, May 24th. Cowen and Company reissued a “buy” rating on shares of Incyte Corporation in a research report on Monday, June 5th. Credit Suisse Group reissued a “buy” rating on shares of Incyte Corporation in a research report on Saturday, June 10th. Raymond James Financial, Inc. reissued a “hold” rating on shares of Incyte Corporation in a research report on Monday, April 17th. Finally, Piper Jaffray Companies reissued a “neutral” rating and issued a $124.00 price objective on shares of Incyte Corporation in a research report on Monday, April 17th. Seven research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $140.39.

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Incyte Corporation by 22.7% in the first quarter. Vanguard Group Inc. now owns 15,415,857 shares of the biopharmaceutical company’s stock valued at $2,060,638,000 after buying an additional 2,847,907 shares during the last quarter. State Street Corp increased its stake in shares of Incyte Corporation by 110.7% in the first quarter. State Street Corp now owns 7,581,684 shares of the biopharmaceutical company’s stock valued at $1,013,437,000 after buying an additional 3,983,207 shares during the last quarter. FMR LLC increased its stake in shares of Incyte Corporation by 8.0% in the first quarter. FMR LLC now owns 2,980,864 shares of the biopharmaceutical company’s stock valued at $398,452,000 after buying an additional 219,923 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Incyte Corporation by 42.0% in the first quarter. Geode Capital Management LLC now owns 1,780,064 shares of the biopharmaceutical company’s stock valued at $237,618,000 after buying an additional 526,163 shares during the last quarter. Finally, UBS Asset Management Americas Inc. increased its stake in shares of Incyte Corporation by 23.9% in the first quarter. UBS Asset Management Americas Inc. now owns 1,477,461 shares of the biopharmaceutical company’s stock valued at $197,492,000 after buying an additional 284,796 shares during the last quarter. Institutional investors and hedge funds own 91.73% of the company’s stock.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Insider Buying and Selling by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.